BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Camrelizumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Camrelizumab\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07602049-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07602049)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Cryoablation Plus Camrelizumab 
 for Advanced Soft Tissue Sarcoma\nEstimated primary completion: 30 Novembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0760
 2049
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07107217-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07107217)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Camrelizumab in Combination Wit
 h Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally 
 Advanced Triple-negative Breast Cancer\nEstimated primary completion: Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/camrelizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7107217
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04208347-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Camrelizumab: Phase 2/3 readout est. (NCT04208347)
DESCRIPTION:Camrelizumab\, phase 2/3\, Gastric Cancer.\nStudy: Perioperativ
 e Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagoga
 stric Cancer\nEstimated primary completion: December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04208347
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07530094-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07530094)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Short-Course Definitive Chemora
 diotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab
  for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma\nEst
 imated primary completion: 1 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07530094
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05139095-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT05139095)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Camrelizumab Plus Apatinib in P
 atients With High-risk Gestational Trophoblastic Neoplasia\nEstimated prim
 ary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/camrelizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05139095
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07143292-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07143292)
DESCRIPTION:Camrelizumab\, phase 2\, Cervical Cancer.\nStudy: A Prospective
 \, Randomized\, Parallel Trial of Famitinib Malate at Different Doses Comb
 ined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervi
 cal Cancer\nEstimated primary completion: 30 December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07143292
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05062837-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Camrelizumab: Phase 2/3 readout est. (NCT05062837)
DESCRIPTION:Camrelizumab\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: He
 patectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC\n
 Estimated primary completion: 30 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05062837
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06121557-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Camrelizumab: Phase 1 readout est. (NCT06121557)
DESCRIPTION:Camrelizumab\, phase 1.\nStudy: Phase I Study of Autologous Tum
 or-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Brea
 st Cancer\nEstimated primary completion: 31 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06121557
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05983237-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Camrelizumab: Phase 1/2 readout est. (NCT05983237)
DESCRIPTION:Camrelizumab\, phase 1/2.\nStudy: Fluzoparib in Combination Wit
 h Camrelizumab and Temozolomide in Advanced Melanoma\nEstimated primary co
 mpletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/camrelizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05983237
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07161791-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Camrelizumab: Phase 1/2 readout est. (NCT07161791)
DESCRIPTION:Camrelizumab\, phase 1/2.\nStudy: Camrelizumab\, Pirfenidone\, 
 and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cance
 r\nEstimated primary completion: 31 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07161791
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06831175-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT06831175)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Phase II Study of PD-1 Inhibito
 r Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal
  Cortical Carcinoma\nEstimated primary completion: 31 December 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06831175
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07238881-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07238881)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Dalpiciclib Plus Camrelizumab f
 or HCC Patients Who Have Previously Received ICI Treatment\nEstimated prim
 ary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/camrelizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07238881
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07167160-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07167160)
DESCRIPTION:Camrelizumab\, phase 2\, Cervical Cancer.\nStudy: Chemo-immunot
 herapy for Cervical Cancer Stage IIICp Trial\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 amrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07167160
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07808853-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07808853)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Node-Sparing Short-Course Radio
 therapy (25 Gy/5 Fractions) Combined With Chemoimmunotherapy as Neoadjuvan
 t Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma：A Pr
 ospective Single-Arm\, Phase II Study\nEstimated primary completion: 31 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/camreliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07808853
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06533384-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Camrelizumab: Phase 3 readout est. (NCT06533384)
DESCRIPTION:Camrelizumab\, phase 3.\nStudy: PARPi or Capecitabine Combined 
 With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC\nEstimated prim
 ary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/camrelizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06533384
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06759090-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT06759090)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Metronomic Capecitabine with Ca
 mrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Canc
 er\nEstimated primary completion: 15 January 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06759090
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059949-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07059949)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Short Course Radiotherapy Follo
 wed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial
  Treatment of Unresectable Metastatic Rectal Cancer\nEstimated primary com
 pletion: 30 January 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/camrelizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07059949
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06745193-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT06745193)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: A Prospective\, Randomized\, Op
 en\, Phase II Clinical Study of Chidamide in Combination with Camrelizumab
  and Apatinib for Advanced Esophageal Cancer\nEstimated primary completion
 : 1 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ca
 mrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06745193
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06360042-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT06360042)
DESCRIPTION:Camrelizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Anti
 -PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment f
 or Unresectable HCC\nEstimated primary completion: 31 March 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06360042
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632405-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT06632405)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: A Trial of Camrelizumab Plus Na
 b-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC\nEstimated
  primary completion: 31 March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/camrelizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06632405
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07618546-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Camrelizumab: Phase na readout est. (NCT07618546)
DESCRIPTION:Camrelizumab\, phase na\, Hepatocellular Carcinoma.\nStudy: A M
 ulticenter\, Randomized\, Open-label\, Controlled Study of HAIC Combined W
 ith Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Rese
 ctable Hepatocellular Carcinoma With High-risk Recurrence Factors\nEstimat
 ed primary completion: 31 March 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/camrelizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07618546
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05576389-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT05576389)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Fluzoparib Combined With Camrel
 izumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negativ
 e Breast Cancer: an Open\, Single Arm\, Multicenter Study\nEstimated prima
 ry completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/camrelizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05576389
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05738616-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Camrelizumab: Phase 3 readout est. (NCT05738616)
DESCRIPTION:Camrelizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Lenv
 atinib Combined With TACE and Camrelizumab in Conversion Resection for Adv
 anced Hepatocellular Carcinoma (LEN-TAC Study)\nEstimated primary completi
 on: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/camre
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05738616
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07159217-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07159217)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Disitamab Vedotin Plus Lenvatin
 ib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract C
 ancer\nEstimated primary completion: 31 May 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07159217
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731153-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT06731153)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: JAK1 Inhibitor Ivarmacitinib Re
 versing Immunotherapy Resistance in TNBC\nEstimated primary completion: Ju
 ne 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/camrelizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067
 31153
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05772273-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Camrelizumab: Phase na readout est. (NCT05772273)
DESCRIPTION:Camrelizumab\, phase na.\nStudy: PD-1 Inhibitor\, Azacitidine a
 nd Low-dose DLI in AML Relapse After Allo-HSCT\nEstimated primary completi
 on: 1 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/camr
 elizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05772273
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07100392-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07100392)
DESCRIPTION:Camrelizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Taur
 oursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatoc
 ellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab\n
 Estimated primary completion: 1 August 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07100392
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07105748-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07105748)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: HAIC Combined With Camrelizumab
  Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HC
 C-CCA)\nEstimated primary completion: 1 August 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07105748
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07491822-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:Camrelizumab: Phase na readout est. (NCT07491822)
DESCRIPTION:Camrelizumab\, phase na.\nStudy: A Single-Arm\, Single-Center\,
  Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy a
 s Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer\nEstim
 ated primary completion: 15 September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07491822
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07627620-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07627620)
DESCRIPTION:Camrelizumab\, phase 2\, Cervical Cancer.\nStudy: Camrelizumab 
 Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent
 / Metastatic Cervical Cancer\nEstimated primary completion: 30 September 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0762762
 0
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06229041-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Camrelizumab: Phase 3 readout est. (NCT06229041)
DESCRIPTION:Camrelizumab\, phase 3.\nStudy: Total Neoadjuvant Treatment ±I
 mmunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)\nEstimate
 d primary completion: 1 October 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/camrelizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06229041
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07312578-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07312578)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Nimotuzumab\,Camrelizumab\, and
  Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous
  Cell Carcinoma\nEstimated primary completion: 1 November 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07312578
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06669611-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20271120
DTEND;VALUE=DATE:20271121
SUMMARY:Camrelizumab: Phase 3 readout est. (NCT06669611)
DESCRIPTION:Camrelizumab\, phase 3\, Nasopharyngeal Carcinoma.\nStudy: Nab-
 TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metasta
 tic Nasopharyngeal Carcinoma\nEstimated primary completion: 20 November 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06669611
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07191977-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07191977)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Neoadjuvant Camrelizumab With P
 albociclib for Resectable Esophageal Squamous Cell Carcinoma\nEstimated pr
 imary completion: December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/camrelizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07191977
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561308-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT06561308)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Clinical Efficacy Study of PD-1
  Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial 
 Cancer\nEstimated primary completion: 1 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06561308
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07016126-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20271222
DTEND;VALUE=DATE:20271223
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07016126)
DESCRIPTION:Camrelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: D-
 BACE in Combination With Chemotherapy and Camrelizumab for Resectable II-I
 IIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC\nEstimated primary c
 ompletion: 22 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/camrelizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07016126
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07334483-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07334483)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: A Study of Yttrium [90Y] Micros
 phere Injection in Combination With Targeted Immunotherapy in the Treatmen
 t of HCC\nEstimated primary completion: 30 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07334483
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896096-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07896096)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Ivarmacitinib Combined With Cam
 relizumab and Fruquintinib for Patients With Metastatic Colorectal Cancer 
 After Failure of Second-line or Later Treatment\nEstimated primary complet
 ion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/camrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07896096
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT06692491)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Study of Precision Treatment fo
 r Rare Tumours in China Guided by PDO and NGS\nEstimated primary completio
 n: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 camrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06692491
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06849492-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT06849492)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: HIM Typing Guides the Treatment
  of Advanced First-Line Triple-Negative Breast Cancer\nEstimated primary c
 ompletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/camrelizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06849492
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06811844-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT06811844)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Two-cycle and Three-cycle Induc
 tion Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
 \nEstimated primary completion: 31 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06811844
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154082-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07154082)
DESCRIPTION:Camrelizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Apat
 inib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy f
 or Hepatocellular Carcinoma\nEstimated primary completion: 31 December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07154082
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07314372-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07314372)
DESCRIPTION:Camrelizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: FAD 
 Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcino
 ma\nEstimated primary completion: 31 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07314372
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05749588-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT05749588)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: FUSCC Refractory TNBC Platform 
 Study (FUTURE2.0)\nEstimated primary completion: 31 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05749588
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07555860-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07555860)
DESCRIPTION:Camrelizumab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Beco
 tatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresecta
 ble Locally Recurrent Nasopharyngeal Carcinoma\nEstimated primary completi
 on: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /camrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07555860
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Fudan University Shanghai Cance
 r Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therap
 y\nEstimated primary completion: 31 December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06423170-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT06423170)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: A Single-arm Phase II Clinical 
 Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for U
 nresectable GBCs\nEstimated primary completion: 31 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06423170
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653451-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Camrelizumab: Phase 2/3 readout est. (NCT07653451)
DESCRIPTION:Camrelizumab\, phase 2/3.\nStudy: Precision Medicine for Immuno
 therapy-Resistant Advanced Esophageal Cancer\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 amrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07653451
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06196671-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT06196671)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Oncolytic Virus Plus PD-1 Inhib
 itor to Patients With Advanced Pancreatic Cancer\nEstimated primary comple
 tion: 1 January 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /camrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06196671
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07324473-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07324473)
DESCRIPTION:Camrelizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Ivar
 macitinib Combined With Camrelizumab and Apatinib for Unresectable Advance
 d Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint T
 herapy: A Single-Arm Exploratory Clinical Study\nEstimated primary complet
 ion: 1 January 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 camrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07324473
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527026-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07527026)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: A Single-arm Phase II Clinical 
 Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Tota
 l Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer\nEsti
 mated primary completion: 1 February 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07527026
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06796803-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20280220
DTEND;VALUE=DATE:20280221
SUMMARY:Camrelizumab: Phase 2/3 readout est. (NCT06796803)
DESCRIPTION:Camrelizumab\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: Ca
 mrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemoth
 erapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellul
 ar Carcinoma(HCC)\nEstimated primary completion: 20 February 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06796803
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07471815-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07471815)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Camrelizumab Plus Risedronate a
 nd Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical
  Study on Mechanisms and Efficacy\nEstimated primary completion: 31 March 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074718
 15
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07787273-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07787273)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Interferon Gamma Plus Camrelizu
 mab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell C
 arcinoma\nEstimated primary completion: 31 March 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07787273
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06361888-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Camrelizumab: Phase 2/3 readout est. (NCT06361888)
DESCRIPTION:Camrelizumab\, phase 2/3.\nStudy: A Phase II/III Trial to Evalu
 ate the Efficacy and Safety of Surufatinib Combined With Camrelizumab\, Na
 b-paclitaxel\, and Gemcitabine in Metastatic Pancreatic Cancer\nEstimated 
 primary completion: 31 May 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/camrelizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06361888
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07639983-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20280605
DTEND;VALUE=DATE:20280606
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07639983)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Multi-Omics-Based Phase Ⅱ Tri
 al of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in
  HER2-Positive Muscle-Invasive Urothelial Carcinoma\nEstimated primary com
 pletion: 5 June 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /camrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07639983
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662681-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Camrelizumab: Phase 1/2 readout est. (NCT07662681)
DESCRIPTION:Camrelizumab\, phase 1/2.\nStudy: Camrelizumab With Famitinib f
 or Patients With Rare Head and Neck Malignancies\nEstimated primary comple
 tion: 1 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ca
 mrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07662681
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06145308-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT06145308)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Precision Treatment of Recurren
 t/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing\nEstimate
 d primary completion: 10 July 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/camrelizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06145308
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06172205-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Camrelizumab: Phase 3 readout est. (NCT06172205)
DESCRIPTION:Camrelizumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Infu
 sional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizu
 mab and Apatinib for Advanced HCC\nEstimated primary completion: 31 July 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0617220
 5
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04803539-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Camrelizumab: Phase 2/3 readout est. (NCT04803539)
DESCRIPTION:Camrelizumab\, phase 2/3.\nStudy: A Prospective\, Phase II Tria
 l Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chem
 otherapy in TNBC\nEstimated primary completion: 1 September 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04803539
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07505186-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07505186)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Camrelizumab\, Chemotherapy and
  Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcin
 oma\nEstimated primary completion: 31 December 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07505186
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622797-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07622797)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Exploratory Clinical Study of C
 amrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserv
 ing Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carc
 inoma\nEstimated primary completion: 31 December 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07622797
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07902713-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07902713)
DESCRIPTION:Camrelizumab\, phase 2\, Nasopharyngeal Carcinoma.\nStudy: Beco
 tatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metast
 atic Nasopharyngeal Carcinoma\nEstimated primary completion: 31 December 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0790271
 3
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589244-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Camrelizumab: Phase 2/3 readout est. (NCT07589244)
DESCRIPTION:Camrelizumab\, phase 2/3.\nStudy: A Study of VRT106\, Combined 
 With Camrelizumab\, and Apatinib for Advanced HCC\nEstimated primary compl
 etion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/camrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07589244
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06889688-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Camrelizumab: Phase 3 readout est. (NCT06889688)
DESCRIPTION:Camrelizumab\, phase 3.\nStudy: Phase III Trial of Camrelizumab
 +Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-
 Negative Breast Cancer\nEstimated primary completion: 31 December 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06889688
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05043688-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Camrelizumab: Phase 3 readout est. (NCT05043688)
DESCRIPTION:Camrelizumab\, phase 3.\nStudy: Camrelizumab Plus Neoadjuvant C
 hemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ES
 CC.\nEstimated primary completion: 31 December 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05043688
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07790419-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Camrelizumab: Phase 4 readout est. (NCT07790419)
DESCRIPTION:Camrelizumab\, phase 4\, Hepatocellular Carcinoma.\nStudy: A Pr
 ospective\, Single-Arm\, Open-Label Clinical Study of the Efficacy and Saf
 ety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Thera
 py and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carc
 inoma and Microvascular Invasion\nEstimated primary completion: 31 Decembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0779
 0419
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07948317-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Camrelizumab: Phase 3 readout est. (NCT07948317)
DESCRIPTION:Camrelizumab\, phase 3.\nStudy: Camrelizumab Plus Nab-Paclitaxe
 l and Cisplatin Before Surgery for Locally Advanced Head and Neck Cancer: 
 a Randomized Phase III Trial\nEstimated primary completion: 1 January 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07948317
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07328009-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07328009)
DESCRIPTION:Camrelizumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Pl
 atform Trial for Personalized and Adaptive Therapies in Hepatocellular Car
 cinoma\nEstimated primary completion: 15 January 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07328009
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400094-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07400094)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Neoadjuvant Chemoimmunotherapy 
 (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC\nEstimated 
 primary completion: February 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/camrelizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07400094
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07395063-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07395063)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: A Clinical Study on the Treatme
 nt of Metastatic Colorectal Cancer at the Second-line or Beyond.\nEstimate
 d primary completion: 1 February 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07395063
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07267806-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Camrelizumab: Phase 3 readout est. (NCT07267806)
DESCRIPTION:Camrelizumab\, phase 3.\nStudy: Camrelizumab and Apatinib With 
 or Without FOLFOX Chemotherapy for Advanced HCC\nEstimated primary complet
 ion: October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ca
 mrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07267806
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07587034-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Camrelizumab: Phase 1/2 readout est. (NCT07587034)
DESCRIPTION:Camrelizumab\, phase 1/2.\nStudy: HAIC-TACE Plus Apatinib and C
 amrelizumab for Liver Cancer\nEstimated primary completion: December 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07587034
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06869226-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT06869226)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: A Multicenter Phase II Clinical
  Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy
  for Organ Preservation in Esophageal Cancer\nEstimated primary completion
 : 31 December 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 amrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06869226
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07466901-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Camrelizumab: Phase na readout est. (NCT07466901)
DESCRIPTION:Camrelizumab\, phase na\, Cervical Cancer.\nStudy: A Single-arm
 \, Multicenter\, Phase II Clinical Study of Camrelizumab Combined With Fam
 itinib in Adjuvant Therapy After Radical Resection of Cervical Cancer\nEst
 imated primary completion: 1 April 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07466901
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06739317-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Camrelizumab: Phase 2/3 readout est. (NCT06739317)
DESCRIPTION:Camrelizumab\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: SB
 RT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patie
 nts with Unresectable Hepatocellular Carcinoma.\nEstimated primary complet
 ion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/camrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06739317
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432087-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Camrelizumab: Phase 3 readout est. (NCT07432087)
DESCRIPTION:Camrelizumab\, phase 3.\nStudy: Camrelizumab Combined With EGFR
  Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locall
 y Advanced Head and Neck Squamous Cell Carcinoma\nEstimated primary comple
 tion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/camrelizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07432087
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06288373-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20310301
DTEND;VALUE=DATE:20310302
SUMMARY:Camrelizumab: Phase 2/3 readout est. (NCT06288373)
DESCRIPTION:Camrelizumab\, phase 2/3\, Cervical Cancer.\nStudy: Neoadjuvant
  Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC\nEstimate
 d primary completion: 1 March 2031. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/camrelizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06288373
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06992336-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20310410
DTEND;VALUE=DATE:20310411
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT06992336)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Circulating Tumor DNA Guided Bo
 ost Therapy in Early Triple Negative Breast Patients With Residual Disease
  After Neoadjuvant Therapy\nEstimated primary completion: 10 April 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/camrelizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06992336
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07521605-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07521605)
DESCRIPTION:Camrelizumab\, phase 2.\nStudy: Short-Course Radiotherapy\, Nal
 -IRI\, Capecitabine\, and Camrelizumab for Locally Advanced MSS Rectal Can
 cer\nEstimated primary completion: 31 December 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07521605
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05981001-1972@assetmemo.bio
DTSTAMP:20261121T004941Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Camrelizumab: Phase 1/2 readout est. (NCT05981001)
DESCRIPTION:Camrelizumab\, phase 1/2.\nStudy: Study of Autologous Tumor-Dra
 ining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Can
 cer\nEstimated primary completion: 30 April 2032. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/camrelizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05981001
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
